Bristol Myers acquires cell therapy partner 2seventy bio

In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma
More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. | More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma,
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal
Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday. Late on Monday, 2seventy said Bristol Myers will acquire all outstanding shares of the company for $5.
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a good deal for BMY or TSVT.
Bristol Meyers Squibb to Acquire 2seventy bio
Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.
BMS to Acquire Abecma Partner 2seventy bio for $286M
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
Bristol Myers Squibb to acquire 2seventy bio for USD 286 million
Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.
Bristol Myers Squibb Acquires 2seventy bio for $286 Million
Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for multiple myeloma.
BioSpace4d
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Average PT from Brokerages
Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...
Yahoo Finance4d
TSVT Up on Acquisition Agreement With BMY for $286 Million
2seventy bio’s board of directors has unanimously recommended that ... manufacturing, and commercialization of Abecma ...